How to buy Homology Medicines stock

Homology Medicines, Inc is a biotechnology business based in the US. Homology Medicines shares (FIXX) are listed on the NASDAQ and all prices are listed in US Dollars. Homology Medicines employs 205 staff and has a trailing 12-month revenue of around 0.00.

Homology Medicines share price

Use our graph to track the performance of FIXX stocks over time.

Homology Medicines shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$6.21 - $17.34
50-day moving average	$8.52
200-day moving average	$10.67
Wall St. target price	$27.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.18

Buy Homology Medicines shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Homology Medicines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Homology Medicines, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Homology Medicines financials

Revenue TTM	$2.7 million
Gross profit TTM	$-97,690,000
Return on assets TTM	-28.35%
Return on equity TTM	-56.63%
Profit margin	0%
Book value	$3.90
Market capitalisation	$389.9 million

TTM: trailing 12 months

Shorting Homology Medicines shares

There are currently 3.4 million Homology Medicines shares held short by investors – that's known as Homology Medicines's "short interest". This figure is 55.4% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Homology Medicines shares can be evaluated.

Homology Medicines's "short interest ratio" (SIR)

Homology Medicines's "short interest ratio" (SIR) is the quantity of Homology Medicines shares currently shorted divided by the average quantity of Homology Medicines shares traded daily (recently around 898378.34224599). Homology Medicines's SIR currently stands at 3.74. In other words for every 100,000 Homology Medicines shares traded daily on the market, roughly 3740 shares are currently held short.

However Homology Medicines's short interest can also be evaluated against the total number of Homology Medicines shares, or, against the total number of tradable Homology Medicines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Homology Medicines's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Homology Medicines shares in existence, roughly 60 shares are currently held short) or 0.0589% of the tradable shares (for every 100,000 tradable Homology Medicines shares, roughly 59 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Homology Medicines.

Find out more about how you can short Homology Medicines stock.

Homology Medicines share dividends

We're not expecting Homology Medicines to pay a dividend over the next 12 months.

Homology Medicines share price volatility

Over the last 12 months, Homology Medicines's shares have ranged in value from as little as $6.21 up to $17.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Homology Medicines's is -0.3221. This would suggest that Homology Medicines's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Homology Medicines has bucked the trend.

Homology Medicines overview

Homology Medicines, Inc. , a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc.

Frequently asked questions

• What percentage of Homology Medicines is owned by insiders or institutions?

  Currently 13.054% of Homology Medicines shares are held by insiders and 65.024% by institutions.

• How many people work for Homology Medicines?

  Latest data suggests 205 work at Homology Medicines.

• When does the fiscal year end for Homology Medicines?

  Homology Medicines's fiscal year ends in December.

• Where is Homology Medicines based?

  Homology Medicines's address is: One Patriots Park, Bedford, MA, United States, 01730

• What is Homology Medicines's ISIN number?

  Homology Medicines's international securities identification number is: US4380831077

• What is Homology Medicines's CUSIP number?

  Homology Medicines's Committee on Uniform Securities Identification Procedures number is: 438083107